From consent to participatory governance: The need for multi-stakeholder alignment in iPSC-based drug repurposing.
Induced pluripotent stem cells (iPSCs) are increasingly used as disease models to accelerate drug repurposing, especially for rare diseases. While ethical and regulatory issues in iPSC research have been widely discussed, little is known about how these challenges are addressed in practice.
Induced pluripotent stem cells (iPSCs) are increasingly used as disease models to accelerate drug repurposing, especially for rare diseases. While ethical and regulatory issues in iPSC research have been widely discussed, little is known about how these challenges are addressed in practice.
What the study was
- Study design
- Journal Article (unspecified)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Stem Cell Reports
Why it surfaced
Matched watchlist topic 'Rare diseases with high unmet need'. Study design: Journal Article (unspecified). Score: 8/10 (N:2, R:3, D:1, P:2).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.